Advertisement

Topics

Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Women’s Cancer

10:30 EDT 12 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
New rucaparib data presented today in two oral plenary sessions Data provide additional insights from ARIEL2 Phase 2 study of rucaparib in advanced ovarian cancer FDA approved Rubraca® (...

Other Sources for this Article

Investor/Analyst:
For Clovis Oncology, Inc.
Anna Sussman, 303-625-5022
asussman@clovisoncology.com
or
Breanna Burkart, 303-625-5023
bburkart@clovisoncology.com

NEXT ARTICLE

More From BioPortfolio on "Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Women’s Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...